NEONC TECHNOLOGIES HOLDINGS, INC. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
NeOnc Technologies announced it will present two posters at the Society for Neuro-Oncology Annual Meeting on November 13, 2026: (1) updated Phase 1/2a results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1-mutant astrocytoma showing durable radiographic remission and prolonged survival, presented by Thomas C. Chen, MD, PhD; and (2) Phase 1 safety and pharmacokinetics data for oral NEO212 in TMZ-resistant recurrent glioblastoma and brain metastases, presented by Josh Neman, PhD. Both presentations occur Friday evening in Philadelphia; no new financial metrics, trial enrollment figures, or material agreements were disclosed.
Why this rating
Routine conference presentation announcement for clinical-stage biotech. No trial results, financing, partnership, regulatory milestone, or quantified clinical endpoints disclosed—only poster presentation notification relative to $67.9M market cap.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.